Monitoring aspirin treatment in patients with thrombocytosis: Comparison of the platelet function analyzer (PFA)-100 with optical aggregometry

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 100-107

  Tsantes, Argirios E ^a   Mantzios, Georgios ^a   Giannopoulou, Vassiliki ^b   Tsirigotis, Panagiotis ^b   Bonovas, Stefanos ^c   Rapti, Evdoxia ^a   Mygiaki, Elissavet ^a   Kartasis, Zafirios ^d   Sitaras, Nikolaos M ^c   Dervenoulas, John ^b   Travlou, Anthi ^a  

^a Blood Bank Unit   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d General Hospital of Chalkida   (Greece)

Author keywords

Aggregometry; Aspirin; PFA 100; Thrombocytosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; AUTOANALYZER; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OPTICAL AGGREGOMETRY; PLATELET FUNCTION ANALYZER; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOSIS;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THROMBOCYTOSIS;

EID: 54149086710     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.008     Document Type: Article

References (33)

1. Bellucci S., Janvier M., and Tobelem G. Essential thrombocythemia: clinical evolutionary and biologic data. Cancer 58 (1986) 2440-2447
2. Harrison C.N. Platelets and thrombosis in myeloproliferative diseases. Hematol Am Soc Hematol Educ Program (2005) 409-415
3. Elliott M.A., and Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128 (2005) 275-290
4. van Genderen P.J., van Vliet H., Prins F.J., van de Moesdijk D., van Strick R., Zijlstra F.J., et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decreased of large von Willebrand factor multimers in plasma. Am Hematol 75 (1997) 215-220
5. Kundu S.K., Heilmann E.J., Sio R., Garcia C., Davidson R.M., and Ostgaard R.A. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 21 (1995) 106-112
6. Jilma B. Platelet function analyzer - PFA-100: a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138 (2001) 152-163
7. Cattaneo M., Federici A.B., and Lecchi A. Evaluation of PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 82 (1999) 35-39
8. Cattaneo M., Lecchi A., and Agati B. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 96 (1999) 213-217
9. Escolar G., Cases A., Vinas M., Pino M., Calls J., Cirera I., et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Hematologica 84 (1999) 614-619
10. Homoncik M., Jilma B., Hergovich N., Stohlawetz P., Panzer S., and Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83 (2000) 316-321
11. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 130 (2005) 3-10
12. Murphy S., Peterson P., and Iland H. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34 (1997) 29-39
13. Avram S., Lupu A., Angelescu S., Olteanu N., and Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med 5 (2001) 79-87
14. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L.M., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
15. Cesar J.M., de Miguel D., Avello A.G., and Burgaleta C. Platelet dysfunction in primary thrombocythemia using the Platelet Function Analyzer, PFA-100. Am J Clin Pathol 123 (2005) 772-777
16. Sucker C., Senft B., Scharf R., and Zotz R. Determination of von Willebrand factor activity: Evaluation of the Haemosil™ assay in comparison with established procedures. Clin Appl Thromb/Hemost 12 (2006) 305-310
17. van Genderen P.J., Mulder P.G., and Waldeboer M. Prevention and treatment of thrombotic complications in ET: efficacy and safety of aspirin. Br J Haematol 97 (1997) 179-184
18. Petrides E.P., and Siegel F. Thrombotic complications in essential thrombocythemia (ET): Clinical facts and biochemical riddles. Blood Cells Mol Dis 36 (2006) 379-384
19. Cortelazzo S., Marchetti M., and Orlando M. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipooxygenase pathway. Am J Hematol 57 (1998) 277-282
20. Raman B.K., Van Slyck E., Riddle J., Sawdyk M.A., Abraham J.P., and Saeed S. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 91 (1989) 647-655
21. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., and Rothwell P.M. Screening for aspirin responsiveness after transient ischemic attack and stroke. Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36 (2005) 1001-1005
22. Malinin A.I., Atar D., Callahan K., McKenzie M., and Serebruany V.L. Effect of a single dose of aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol 462 (2003) 139-143
23. Breddin H.K. Can platelet aggregometry be standardized?. Platelets 16 (2005) 151-158
24. De Gaetano G., and Cerleti C. Aspirin resistance: a revival of platelet aggregation tests?. J Thromb Haemost 1 (2003) 2048-2050
25. Patrono C. Aspirin resistance: definition, mechanisms and clinical reads-outs. J Thromb Haemost 1 (2003) 1710-1713
26. Francis J., Francis D., Larson L., Helms E., and Garcia M. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice?. Platelets 10 (1999) 132-136
27. Marshall P.W., Williams A.J., Dixon R.M., Growcott J.W., Warburton S., Armstrong J., et al. A comparison of the effects of aspirin on bleeding time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 44 (1997) 151-155
28. Chakroun T., Gerotziafas G., Robert F., Lecrubier C., Samama M.M., Hatmi M., et al. In vitro aspirin resistance detected by PSA-100TM closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 124 (2004) 80-85
29. Troost M.M., and van Genderen P.J. Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA-100. Ann Hematol 81 (2002) 352-353
30. Favaloro E.J. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 7 (2001) 170-179
31. Storey R.F., and Heptinstall S. Laboratory investigation of platelet function. Clin Lab Haematol 21 (1999) 317-329
32. McDabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Lawrie A.S., Purdy G., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16 (2005) 269-280
33. van Genderen P.J., Budde U., Michiels J., van Strik R., and van Vliet H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. Br J Haematol 93 (1996) 962-965